Press Release
Barcelona, November 2016
Asphalion attended the Elastislet consortium meeting in Athens with the European Commission independent expert.
The University of Valladolid organized the fourth progress meeting of Elastislet project and consortium which was held last Thursday 24th November at the Sofitel Athens Airport Hotel in Athens. The event was attended by an independent expert and most of the partners of the project.
The meeting confirmed the good health of the project as it enters a critical phase of gestation with several key milestones being achieved and others pending soon. This month, November, is month 18 of the project and the first reporting period will be finalized with a positive balance.
Asphalion will participate in a briefing meeting with the Innovation Task Force (ITF) at the European Medicines Agency (EMA) as part of an early dialogue regarding Elastislet project and one of the ongoing tasks of the consortium. All initial signs are positive and this meeting should go ahead in the first quarter of 2017. Asphalion is the partner in charge of compiling all the data and information generated within the project and preparing from it the required regulatory documents to be submitted to the EMA. One of the key developments to come out of the lengthy discussion in the Athens meeting was a clearer regulatory definition and developmental focus of the project which has helped the progress of the ITF meeting preparations.
ELASTISLET : The project
Tailored elastin-like recombinamers as advanced systems for cell therapies in diabetes mellitus: a synthetic biology approach towards a bioeffective and immunoisolated biosimilar islet/cell niche.
This project has received funding from the European Union?s Horizon 2020 research and innovation programme under grant agreement No 646075.
ELASTISLET was funded by the European commission under the EU Framework Programme H2020 within NMP10 ? 2014: Biomaterials for the treatment of diabetes mellitus.
ELASTISLET aims to create a breakthrough development in encapsulation technology and its use in cell and tissue therapies for the treatment of type 1 and 2 diabetes.
ELASTISLET will combine leading technologies in biomaterial design, production and processing, cross-linking/grafting technology and cell therapy, to synergistically integrate them into a new immune-isolation and biomimetic scaffolding approach for islet and cell transplantation in diabetes treatment. ELASTISLET?s starting point is a highly innovative and versatile family of superior biomaterials, the Elastin-like Recombinamers (ELRs). Those innovative materials will be combined with the most cutting-edge encapsulation technologies, such as reactive LbL. ELASTISLET relies on the most innovative ideas taken from synthetic biology, nanobiotechnology and molecular and cellular biology to build the ideal niche for islet/cell encapsulation and transplantation.
ELASTISLET brings together leading experts in biomaterials, health sciences and industry from 9 countries to reach an advanced system for cell therapies in diabetes mellitus.
About Asphalion:
ASPHALION is an International Scientific and Regulatory Affairs consultancy firm based in Barcelona and Munich. We offer comprehensive services for Drug Development and Regulatory Affairs to Pharma, Biotech and Medical Devices companies.
Since 2000, we have consistently grown and now have over 70 professional consultants with backgrounds in Life sciences (Pharmacy, Chemistry, Biology, Biochemistry, Biotechnology, Medicine and Veterinary Medicine). Our consultants are experts in their field and are in direct contact with EU agencies (EMA and NCAs) for the development and implementation of new regulatory standards.
Asphalion provides a global range of services, for global clients.
Our services range from early development, throughout the registration, until marketing and post-commercialization phases of your product.
Through our network of regulatory consultants, Asphalion is in a position to support your worldwide scientific & regulatory activities. We make use of a dedicated US agent in the fields of Pharma/Biotech, Medical Devices and In Vitro Diagnostics.
Asphalion is actively participating in Horizon 2020 programme as a member of many project consortiums under this European Commission’s initiative that brings research ideas into the market.
Elastislet: This research project has received funding from the EU’s H2020 framework programme for research and innovation under grant aggreement n. 646075.
